Weil W M, Linton G F, Whiting-Theobald N, Vowells S J, Rafferty S P, Li F, Malech H L
Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-1886, USA.
Blood. 1997 Mar 1;89(5):1754-61.
Chronic granulomatous disease (CGD) can result from any of four single gene defects involving the components of the superoxide (O-2) generating phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. We show that transduction of peripheral blood CD34+ hematopoietic progenitors from a p67phox deficient CGD patient with replication defective amphotropic retrovirus encoding p67phox (MFGS-p67phox) significantly corrected the CGD functional defect in phagocyte oxidase activity in vitro. Using a chemiluminescence assay of oxidase activity, we showed that transduced patient CD34+ progenitors differentiating to myeloid cells in culture produced 25% of the total superoxide produced by normal CD34+ progenitors differentiating in culture. A flow cytometric assay of oxidase activity used to assess the oxidase function of individual cells in the cultures indicated that up to 32% of maturing granulocytes derived from transduced CD34+ progenitors from the p67phox CGD patient were oxidase positive with the average level of correction per granulocyte of 85% of that seen with granulocytes in similar cultures of CD34+ progenitors from normal volunteers. Nitroblue tetrazolium dye reduction assays of colonies of transduced progenitors in soft agar indicated that in some studies restoration of oxidase activity occurred in myeloid cells within 44% of granulocyte-erythrocyte-monocyte colonies, and within 28% of the combined group of granulocyte colonies/monocyte colonies/granulocyte monocyte colonies. These high correction rates were achieved without any selective regimen to enrich for transduced cells. This study provides a basis for development of gene therapy for the p67phox deficient form of CGD.
慢性肉芽肿病(CGD)可由涉及超氧化物(O-2)生成性吞噬细胞烟酰胺腺嘌呤二核苷酸磷酸(NADPH)氧化酶成分的四种单基因缺陷中的任何一种引起。我们发现,用编码p67phox的复制缺陷型双嗜性逆转录病毒(MFGS-p67phox)转导来自一名p67phox缺陷型CGD患者的外周血CD34+造血祖细胞,可在体外显著纠正吞噬细胞氧化酶活性方面的CGD功能缺陷。通过氧化酶活性的化学发光测定,我们发现转导的患者CD34+祖细胞在培养中分化为髓细胞时,产生的超氧化物总量是正常CD34+祖细胞在培养中分化产生的超氧化物总量的25%。用于评估培养物中单个细胞氧化酶功能的氧化酶活性流式细胞术测定表明,来自p67phox CGD患者的转导CD34+祖细胞产生的成熟粒细胞中,高达32%的细胞氧化酶呈阳性,每个粒细胞的平均校正水平为正常志愿者CD34+祖细胞类似培养物中粒细胞的85%。软琼脂中转导祖细胞集落的硝基蓝四氮唑染料还原测定表明,在一些研究中,氧化酶活性的恢复发生在粒细胞-红细胞-单核细胞集落的44%以内的髓细胞中,以及粒细胞集落/单核细胞集落/粒细胞单核细胞集落组合的28%以内的髓细胞中。在没有任何富集转导细胞的选择方案的情况下,实现了这些高校正率。本研究为开发针对p67phox缺陷型CGD的基因治疗提供了基础。